Sensyne Health, a UK-based company focused on artificial intelligence in health care, plans to raise 60 million pounds ($78 million) from initial public offering (IPO).
The IPO is expected to give the company a post-money valuation of around 225 million pounds.
The company aims to be a docking station between the pharmaceutical industry and the national health services (NHS), making the analysis of anonymized NHS data available under proper Chinese walls and controls.
Insights gained from studying the detailed databases will be sold on to pharmaceutical companies to help in drug research, including the design of smarter clinical trials.